FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
-0.39%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$581M
AUM Growth
+$581M
(-7.8%)
Cap. Flow
-$5.61M
Cap. Flow
% of AUM
-0.96%
Top 10 Holdings %
Top 10 Hldgs %
85.53%
Holding
19
New
3
Increased
3
Reduced
–
Closed
3
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
$28.3M |
| 2 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
$16.6M |
| 3 |
Geron
GERN
|
$15.4M |
| 4 |
Merus
MRUS
|
$6.89M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$5.06M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$33.8M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$29.2M |
| 3 |
Annexon
ANNX
|
$17.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$6.05B
| $124M | 21.34% | 2,011,647 | – | – |
|
2
Nuvalent
NUVL
$5.52B
| $75.3M | 12.94% | 2,884,492 +95,511 | +3% | +$2.49M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $62.8M | 10.8% | 3,127,429 +251,903 | +9% | +$5.06M |
|
|
ONC
4
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $51.6M | 8.88% | 239,443 | – | – |
|
|
5
Enliven Therapeutics
ELVN
$1.2B
| $42.2M | 7.25% | 1,924,938 +1,293,605 | +205% | +$28.3M |
|
6
Viridian Therapeutics
VRDN
$1.5B
| $34.8M | 5.99% | 1,369,623 | – | – |
|
7
Cogent Biosciences
COGT
$1.69B
| $29.8M | 5.12% | 2,758,975 | – | – |
|
8
argenx
ARGX
$43.6B
| $27.4M | 4.71% | 73,526 | – | – |
|
9
Astria Therapeutics
ATXS
$349M
| $25.3M | 4.35% | 1,901,397 | – | – |
|
10
Terns Pharmaceuticals
TERN
$609M
| $24.2M | 4.15% | 2,040,000 | – | – |
|
11
Tyra Biosciences
TYRA
$675M
| $22.8M | 3.92% | 1,416,998 | – | – |
|
|
THRX
12
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $16.6M | 2.85% | +1,865,671 | New | +$16.6M |
|
|
13
Geron
GERN
$893M
| $15.4M | 2.65% | +7,104,358 | New | +$15.4M |
|
|
DBVT
14
DBV Technologies
DBVT
$264M
| $11.9M | 2.05% | 7,064,964 | – | – |
|
15
Trevi Therapeutics
TRVI
$883M
| $10.5M | 1.81% | 5,696,515 | – | – |
|
|
16
Merus
MRUS
$4.98B
| $6.89M | 1.18% | +374,435 | New | +$6.89M |
|
|
17
Annexon
ANNX
$226M
| – | – | -3,358,563 | Closed | -$17.4M |
|
|
18
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – | -2,543,107 | Closed | -$29.2M |
|
|
19
Neurocrine Biosciences
NBIX
$13.8B
| – | – | -283,000 | Closed | -$33.8M |
|